EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study

Corentin Orvain iD, Sarah Bertoli iD, Pierre Peterlin, Yohann Desbrosses, Pierre-Yves Dumas, Alexandre Iat iD, Marie-Anne Hospital, Martin Carre, Emmanuelle Tavernier iD, Jérémie Riou iD, Anne Bouvier iD, Audrey Bidet iD und 9 weitere

Leukemia · 2024-09 · 38 (9) · 1949-1957

DOI: 10.1038/s41375-024-02335-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, online erschienen am 17.07.2024. Verfasst von Corentin Orvain und 20 weiteren Autor:innen. Beteiligte Einrichtung: Maladies du Sang, CHU d'Angers, Angers, France. Hauptthemen laut MEDLINE: Nucleophosmin, Leukemia, Myeloid, Acute, Nuclear Proteins, Mutation. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with Core-Binding Factor (CBF) and NPM1 -mutated acute myeloid leukemia (AML) can be monitored by quantitative PCR after having achieved first complete remission (CR) to detect morphologic relapse and drive preemptive therapy. How to best manage these patients is unknown. We retrospectively analyzed 303 patients with CBF and NPM1 -mutated AML, aged 18–60 years, without allogeneic hematopoietic cell transplantation (HCT) in first CR, with molecular monitoring after first-line intensive therapy. Among these patients, 153 (51%) never relapsed, 95 (31%) had molecular relapse (53 received preemptive therapy and 42 progressed to morphologic relapse at salvage therapy), and 55 (18%) had upfront morphologic relapse. Patients who received preemptive therapy had higher OS than those who received salvage therapy after having progressed from molecular to morphologic relapse and those with upfront morphologic relapse (three-year OS: 78% vs . 51% vs . 51%, respectively, P = 0.01). Preemptive therapy included upfront allogeneic HCT ( n = 19), intensive chemotherapy ( n = 21), and non-intensive therapy ( n = 13; three-year OS: 92% vs . 79% vs . 58%, respectively, P = 0.09). Although not definitive due to the non-randomized allocation of patients to different treatment strategies at relapse, our study suggests that molecular monitoring should be considered during follow-up to start preemptive therapy before overt morphologic relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NucleophosminLeukemia, Myeloid, AcuteNuclear ProteinsMutationHumansAdultMiddle AgedFemaleMaleAdolescentYoung AdultRetrospective StudiesRecurrenceHematopoietic Stem Cell TransplantationCore Binding FactorsPrognosisSalvage TherapyRemission InductionAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, Local

Substanzen

NucleophosminNPM1 protein, humanNuclear ProteinsCore Binding Factors

Autor:innen und Institutionen

  • Maladies du Sang, CHU d'Angers, Angers, France.
  • Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, FHU-GOAL, Nantes, France.
  • Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, F-49000, Angers, France.
  • Hématologie Clinique, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
  • Hématologie Clinique, CHU de Nantes, Nantes, France.
  • Hematologie Clinique, CHU de Besançon, Besançon, France.

ORCID-Profile: Corentin Orvain, Sarah Bertoli, Alexandre Iat, Emmanuelle Tavernier, Jérémie Riou, Anne Bouvier, Audrey Bidet, Florian Renosi, Eric Delabesse, Arnaud Pigneux, Mathilde Hunault-Berger

Zitieren

APA

Orvain, C., Bertoli, S., Peterlin, P., Desbrosses, Y., Dumas, P. Y., Iat, A., Hospital, M. A., Carre, M., Tavernier, E., Riou, J., Bouvier, A., Bidet, A., Tondeur, S., Renosi, F., Mozziconacci, M. J., Flandrin-Gresta, P., Dadone-Montaudié, B., Delabesse, E., Pigneux, A., …, & Recher, C. (2024). Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study. Leukemia, 38(9), 1949-1957. https://doi.org/10.1038/s41375-024-02335-2

Vancouver

Orvain C, Bertoli S, Peterlin P, Desbrosses Y, Dumas PY, Iat A, et al. Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study. Leukemia. 2024;38(9):1949-1957. doi:10.1038/s41375-024-02335-2

BibTeX
@article{Orvain2024,
  author = {Orvain, Corentin and Bertoli, Sarah and Peterlin, Pierre and Desbrosses, Yohann and Dumas, Pierre-Yves and Iat, Alexandre and Hospital, Marie-Anne and Carre, Martin and Tavernier, Emmanuelle and Riou, Jérémie and Bouvier, Anne and Bidet, Audrey and Tondeur, Sylvie and Renosi, Florian and Mozziconacci, Marie-Joelle and Flandrin-Gresta, Pascale and Dadone-Montaudié, Bérengère and Delabesse, Eric and Pigneux, Arnaud and Hunault-Berger, Mathilde and Recher, Christian},
  title = {Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia – a FILO study},
  journal = {Leukemia},
  year = {2024},
  volume = {38},
  number = {9},
  pages = {1949--1957},
  doi = {10.1038/s41375-024-02335-2}
}
Kostenlos starten →